START FREE TRIAL
Home Healthcare Revvity

Revvity

$19.00

SKU: RVTY Category:

Description

Revvity Delivers 7% Organic Growth as Adjusted Operating Margin Reaches 28.7%!

 

Revvity, Inc. reported its financial results for the third quarter of 2026, showing a mixed but generally positive performance. Total revenue was $729 million, up from $699 million in the prior-year period, reflecting a 7% pro forma organic revenue growth when excluding the impact of foreign exchange and portfolio changes. The company’s Life Sciences segment exhibited stronger growth with an 11% increase in pro forma revenue and 9% organic growth, while Diagnostics segment revenue declined slightly on a reported basis but showed 4% pro forma and 5% organic growth. Profitability improved as GAAP earnings per share (EPS) from continuing operations rose to $0.56 from $0.41 a year ago, and adjusted EPS increased to $1.38 from $1.18. On a pro forma basis, excluding the Immunodiagnostics business in China which is slated for divestiture, EPS stood at $0.60 (GAAP) and $1.37 (adjusted), both showing significant gains compared to the prior year.